The influence of prolonged lidoflazine (R 7904) treatment on resting ECG, heart rate and blood pressure. A retrospective study.
Resting ECGs of 172 patients (33-77 years) with anginal complaints, who had been treated for several months with lidoflazine 120-360 mg/day, together with all available data on blood pressure and heart rate were collected and analysed over a period of at least one year after the start of lidoflazine treatment. Both systolic and diastolic blood pressure decreased significantly from the sixth month onwards; heart rate and P-duration decreased gradually, whereas (TI-TIII) and (TV6-TV1) increased significantly. Data also showed that prolonged treatment with lidoflazine favourably influences typical ischaemia-related ECG aberrations in angina pectoris patients.
D000328:Adult; D000368:Aged; D000787:Angina Pectoris / Q000188:drug therapy*; D001794:Blood Pressure / Q000187:drug effects*; D004562:Electrocardiography; D005260:Female; D006321:Heart / Q000187:drug effects*; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008013:Lidoflazine / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*
D010879:Piperazines; D008013:Lidoflazine